RADNOR, Pa., Aug. 21, 2024 /PRNewswire/ -- law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the comp ...

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

文章核心观点 - 尽管DexCom和Novartis公司面临一些短期挑战,但它们仍有长期增长潜力,值得投资[1][2][3] DexCom公司 - DexCom公司是一家专注于糖尿病连续血糖监测设备的医疗器械公司,其股价在过去10年中表现优于市场[4] - 公司最近的业绩受到了一些因素的影响:1)新客户增长速度低于预期[5] 2)最新产品G7的折扣优惠力度大于预期,导致客户收入下降,但这是短期问题[6] - 公司面临的更重要问题是如何保持对阿博特实验室的竞争优势,但全球糖尿病患者中只有1%使用了连续血糖监测技术,仍有巨大的市场机会[7][8] - 公司正在开发更便宜的产品如DexCom One,以进一步拓展全球市场[9] - 总的来说,DexCom公司的收入和利润有望继续保持增长,未来仍有较强的市场竞争力[10] Novartis公司 - Novartis是一家大型制药公司,业务较为稳定,适合风险厌恶型投资者[11] - 公司最近剥离了仿制药业务,将专注于开发全新药物,这有助于提升公司的业绩增长[12] - 公司二季度收入和调整后每股收益均有不错的增长[13] - Novartis是一家优质的股息股,已连续27年增加派息,体现了公司稳健的经营[14]

Look beyond share price at the business behind the stock, and you might find there's more for investors to consider.If you're looking for stocks on sale in the current market, despite the broader gains that major indices have clocked, many companies have responded in different ways. While a stock trading at a discount isn't in itself a reason to hit the buy button, great businesses are sometimes beaten down by investor sentiment and can present opportunities for the forward-thinking individual.Here are two ...

NEW YORK, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

文章核心观点 - 魁北克省将Dexcom G7连续血糖监测(CGM)系统纳入公共处方药保险计划,为患有1型糖尿病的居民提供覆盖[1][2][3][4] - Dexcom G7是一款创新有效的糖尿病管理解决方案,可以帮助患者更好地控制血糖,改善生活质量[5][6][7][8] - 数字糖尿病管理市场前景广阔,Dexcom有望从中获益[9][10][11] 行业概况 - 数字糖尿病管理市场规模预计将从2023年的189亿美元增长到2028年的358亿美元,年复合增长率为13.6%[9][10] - 市场增长驱动因素包括糖尿病护理解决方案的不断升级、技术进步以及连接设备和应用程序的使用日益普及[10] 公司动态 - Dexcom最近获得FDA批准推出无需处方即可购买的Stelo葡萄糖生物传感器,进一步方便了消费者获取先进的CGM技术[12] - Dexcom G7 CGM系统与Tandem Diabetes Care的t:slim X2胰岛素泵实现了首次AID集成[13] - Dexcom在爱尔兰盖尔韦郡建成了新的先进制造设施,有望为欧洲、中东和非洲地区的糖尿病患者带来福音[14] 财务表现 - 2023年初至今,Dexcom股价下跌41.7%,而同期医疗行业上涨6.8%,标准普尔500指数上涨16.2%[15]

Here's why DexCom should be on your radar after the company's share price plunged recently.Attractive investment opportunities can sometimes arise when investors react emotionally to short-term events. Some of these events revolve around the earnings season, when a company releases financial results that fall short of analysts' expectations. It can be a miss involving just a penny or two, but the stock will still get sold down savagely. Such was the case for DexCom (DXCM 3.30%), a manufacturer of continuous ...

文章核心观点 - 公司DexCom是一家从事糖尿病管理的葡萄糖监测系统开发商 [3] - 公司最近进行了销售团队重组,并表示GLP-1减肥药物与公司产品具有互补性 [3] - 公司在2024年第二季度业绩表现不佳,全年收入指引从43.5亿美元下调至40亿-40.5亿美元 [4] - 公司将业绩下滑归因于销售团队重组带来的挑战,但也有分析师质疑GLP-1治疗剂的热销是否产生了影响 [4] - 公司股价在7月26日开盘时暴跌38%,从107.85美元/股下跌至66.60美元/股 [5] 公司相关 - 公司开发了用于糖尿病管理的葡萄糖监测系统 [3] - 公司最近进行了销售团队重组,并表示GLP-1减肥药物与公司产品具有互补性 [3] - 公司在2024年第二季度业绩表现不佳,全年收入指引从43.5亿美元下调至40亿-40.5亿美元 [4] - 公司将业绩下滑归因于销售团队重组带来的挑战 [4] 行业相关 - 分析师质疑GLP-1治疗剂的热销是否对公司业绩产生了影响 [4] - 公司股价在7月26日开盘时暴跌38%,从107.85美元/股下跌至66.60美元/股 [5]

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) (“DexCom”). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that ...

RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the ...